COVID-19 Impact on Recovered Patients with Chronic Diseases

How will COVID-19 impact recovered patients with chronic diseases? 

 

Currently, the primary focus of the pharma industry is on creating therapies, vaccines, and antibodies to help humanity during the COVID-19 pandemic. The goal of their crucial efforts is to return the world to some type of “normal.”

 

It is well documented that patients with conditions such as Type 2 Diabetes, serious heart conditions (including Heart Failure, Coronary Heart Disease, and Cardiomyopathy), COPD, Chronic Kidney Disease, Immunocompromised State, Solid Tumor Transplant, Sickle Cell Disease and BMI >30 are at the highest risk for COVID-19.

 

A critical question requiring further investigation is: what will be the long-term effects of the coronavirus on various disease states and existing therapy management?

 

A close examination of the COVID-19 patient journey will result in a better understanding of the impact of the virus on at-risk diabetes patients. Segmenting positive and negative COVID-19 diabetes patients provides a real world comparison of anonymized patient cohorts’ A1C, fasting blood sugars, and glucose levels. Linked with prescribed medications, this data will identify the COVID-19  impact on the patients’ prescribed drug therapy.

 

The MSA Healthcare Data Management team’s proven expertise in patient-level data de-identification, aggregation, and integration provides an up to 360° COVID-19-patient journey by linking clinical lab results, prescriptions, EMR and medical claims from multiple disparate sources while protecting patient privacy. The unrivaled services and solutions provided by MSA enable pharma to visualize the (immediate and long-term) COVID-19 impact on in-line brands.

 

To learn more, contact the HCDM Team. Visit us at hcdm.msa.com and follow us on LinkedIn.